Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJNQ9K)

• Drug Name: Octanedioic acid bis-hydroxyamide Drug Info
• Synonyms: Suberohydroxamic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5173
  ChEBI ID: CHEBI:125584
  TTD Drug ID: DMJNQ9K

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase 6 (HDAC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Citarinostat	DMQLODU	Multiple myeloma	2A83	Phase 1	[4]
KA2507	DMW0H9Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[5]

Drug(s) Targeting Histone deacetylase 8 (HDAC8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NBM-BMX	DM5OWXA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[5]

Drug(s) Targeting Histone deacetylase 2 (HDAC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CHR-3996	DMIXPNG	Lymphoma	2A80-2A86	Phase 1/2	[7]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[5]

Drug(s) Targeting Histone deacetylase 4 (HDAC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-61	DMXH1G3	N. A.	N. A.	Patented	[5]
PMID29671355-Compound-45a	DM5LYKR	N. A.	N. A.	Patented	[5]

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[8]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[9]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[4]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[10]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[11]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[12]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[4]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[13]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[14]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[15]

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[16]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[17]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[16]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[15]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[18]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[19]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[12]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[20]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[16]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[21]

Drug(s) Affected By Putative POTE ankyrin domain family member M (POTEM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[23]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[3]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[3]
Nabiximols	DMHKJ5I	Cancer related pain	MG30	Phase 3	[25]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[26]
Tacedinaline	DM1Z74X	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[3]

Drug(s) Affected By G-protein coupled receptor 183 (GPR183)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[27]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[28]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[3]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[29]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[31]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[3]

Drug(s) Affected By Sestrin-3 (SESN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[34]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[35]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[36]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[37]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[38]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[40]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[41]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[42]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[43]

Drug(s) Affected By Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[44]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[37]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[45]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[46]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[45]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[48]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[49]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[50]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[43]

Drug(s) Affected By Cyclin-dependent kinase 5 activator 1 (CDK5R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[36]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[52]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[54]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[54]

Drug(s) Affected By INO80 complex subunit D (INO80D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[55]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[56]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[59]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[3]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[61]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[62]

Drug(s) Affected By 7SK snRNA methylphosphate capping enzyme (MEPCE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[63]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[3]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[65]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[66]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[61]

Drug(s) Affected By TBC1 domain family member 16 (TBC1D16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[68]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[65]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[69]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[3]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[70]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]

Drug(s) Affected By Protein Jumonji (JARID2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[3]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[3]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[73]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[74]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]

Drug(s) Affected By ELL-associated factor 2 (EAF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[36]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[76]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[78]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[79]

Drug(s) Affected By Bcl-2-modifying factor (BMF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[81]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[82]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[47]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[84]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[85]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[50]

Drug(s) Affected By Sialidase-1 (NEU1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[86]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[87]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[37]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[31]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[88]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[69]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]

Drug(s) Affected By Pre-mRNA-splicing factor RBM22 (RBM22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[48]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[65]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[59]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[66]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[61]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[89]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[90]
Scriptaid	DM9JZ21	Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]

Drug(s) Affected By Ral guanine nucleotide dissociation stimulator-like 1 (RGL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[91]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[73]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[36]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[92]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[93]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[68]

Drug(s) Affected By RWD domain-containing protein 3 (RWDD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[3]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[78]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[65]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[94]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[3]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[3]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[90]

Drug(s) Affected By DmX-like protein 1 (DMXL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[36]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[95]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[96]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[97]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[65]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[59]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[98]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[2]
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[1]
Histone deacetylase 2 (HDAC2)	TTSHTOI	HDAC2_HUMAN	Inhibitor	[1]
Histone deacetylase 4 (HDAC4)	TTTQGH8	HDAC4_HUMAN	Inhibitor	[1]
Histone deacetylase 6 (HDAC6)	TT5ZKDI	HDAC6_HUMAN	Inhibitor	[1]
Histone deacetylase 8 (HDAC8)	TTT6LFV	HDAC8_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
7SK snRNA methylphosphate capping enzyme (MEPCE)	OTRBQEYP	MEPCE_HUMAN	Gene/Protein Processing	[3]
Bcl-2-modifying factor (BMF)	OT90NSLI	BMF_HUMAN	Gene/Protein Processing	[3]
Cyclin-dependent kinase 5 activator 1 (CDK5R1)	OTJELWK0	CD5R1_HUMAN	Gene/Protein Processing	[3]
DmX-like protein 1 (DMXL1)	OTWVL31L	DMXL1_HUMAN	Gene/Protein Processing	[3]
ELL-associated factor 2 (EAF2)	OTSOET5L	EAF2_HUMAN	Gene/Protein Processing	[3]
G-protein coupled receptor 183 (GPR183)	OTRILX7G	GP183_HUMAN	Gene/Protein Processing	[3]
INO80 complex subunit D (INO80D)	OTY39R4P	IN80D_HUMAN	Gene/Protein Processing	[3]
Pre-mRNA-splicing factor RBM22 (RBM22)	OTFW0IGK	RBM22_HUMAN	Gene/Protein Processing	[3]
Protein Jumonji (JARID2)	OT14UM8H	JARD2_HUMAN	Gene/Protein Processing	[3]
Putative POTE ankyrin domain family member M (POTEM)	OT7L2HGH	POTEM_HUMAN	Gene/Protein Processing	[3]

References

• [1] Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309.
• [2] Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
• [3] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
• [6] Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
• [7] A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
• [8] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [9] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [12] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [13] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [14] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [15] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [16] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [17] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [18] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [19] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [20] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [21] 2011 Pipeline of 4SC AG.
• [22] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [23] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [24] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [25] Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16.
• [26] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [27] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [28] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [29] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [30] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [31] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [32] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [33] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [34] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [35] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [36] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [37] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [38] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [39] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [40] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [41] Capsaicin inhibits the migration, invasion and EMT of renal cancer cells by inducing AMPK/mTOR-mediated autophagy. Chem Biol Interact. 2022 Oct 1;366:110043. doi: 10.1016/j.cbi.2022.110043. Epub 2022 Aug 28.
• [42] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [43] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [44] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [45] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [46] RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis. 2004 Sep;9(5):561-71. doi: 10.1023/B:APPT.0000038030.47068.49.
• [47] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [48] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [49] Gallic acid protects against ethanol-induced hepatocyte necroptosis via an NRF2-dependent mechanism. Toxicol In Vitro. 2019 Jun;57:226-232. doi: 10.1016/j.tiv.2019.03.008. Epub 2019 Mar 7.
• [50] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [51] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [52] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [53] Systematic transcriptome-based comparison of cellular adaptive stress response activation networks in hepatic stem cell-derived progeny and primary human hepatocytes. Toxicol In Vitro. 2021 Jun;73:105107. doi: 10.1016/j.tiv.2021.105107. Epub 2021 Feb 3.
• [54] Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
• [55] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [56] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [57] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [58] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [59] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [60] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [61] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [62] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [63] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [64] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [65] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [66] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [67] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [68] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [69] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [70] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [71] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [72] Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines. Differentiation. 2012 Nov;84(4):330-43. doi: 10.1016/j.diff.2012.07.006. Epub 2012 Aug 18.
• [73] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [74] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [75] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [76] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [77] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [78] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [79] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [80] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [81] Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009 May;8(5):1197-206.
• [82] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010 Feb;15(2):219-29. doi: 10.1007/s10495-009-0424-9.
• [83] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [84] Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
• [85] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [86] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [87] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [88] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [89] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [90] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [91] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [92] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [93] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [94] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [95] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [96] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [97] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [98] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.